Journals / Selçuk Tıp Dergisi / 2001 / Cilt: 17 - Sayı: 1

The clinical usefulness of the tumor markers; AFP, CEA, CA 125 and CA 19-9 in patients with gastric cancer

Mide kanserli olgularda tümör "marker"larında AFP, CEA, CA 125 ve CA19-9'un klinik kullanımlarının incelenmesi

Pages
37–42
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In conclusion, tumor markers, especially CA 125 and CA 19-9 can be used in clinical applications (e.g. diagnosis, preoperative evaluation and follow up etc.) of gastric cancers.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:In this study, we aimed to investigate; diagnostic usefulness and sensitivity-specisifity values of some of the tumor markers (such as:CEA, CA 19-9, CA 125, and AFP) in totally 112 patients (75 male, 37 female) with gastric cancer.
📊
Key Findings & Data:Gastric cancer group; the 57 patients (38 male, 17 female) mean age 55.36±1.37 years, benign disease group; the 30 patients (20 male, 10 female) mean age 53.53±1.97 years, control group; the 25 healtly (17 male, 8 female) mean age 57.11±2.87 years.
💡
Conclusion & Impact:In conclusion, tumor markers, especially CA 125 and CA 19-9 can be used in clinical applications (e.g. diagnosis, preoperative evaluation and follow up etc.) of gastric cancers.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Karsinoembriyonik antijen · Tümör belirteci · biyolojik

Abstract

In this study, we aimed to investigate; diagnostic usefulness and sensitivity-specisifity values of some of the tumor markers (such as:CEA, CA 19-9, CA 125, and AFP) in totally 112 patients (75 male, 37 female) with gastric cancer. Gastric cancer group; the 57 patients (38 male, 17 female) mean age 55.36±1.37 years, benign disease group; the 30 patients (20 male, 10 female) mean age 53.53±1.97 years, control group; the 25 healtly (17 male, 8 female) mean age 57.11±2.87 years. No statistical significant difference was found between the groups for age and sex (p>0.05). Preoperative tumor marker values; CEA, CA 125 and CA 19-% levels in gastric cancer group were found to be highly significiant among benign disease and control groups (p<0.05). Postoperative tumor marker values; CA 125 and CA 19-9 levels in gastric cancer group were found to be highly significant control group (p<0.05), but only CA 125 level were found to be highly significant benign disease group (p<0.05). Preoperative tumor marker value; No statistical significant difference was found between benign disease group and control group from all of the tumor marker levels (p>0.05). Postoperative tumor marker values; CA 19-9 levels in benign disease group were found to be highly significant control group (p<0.01). The sensitivity and specificity of AFP were 3.5-100%, sensitivity and specificity of CEA were 63-100%, sensitivity and specificity of CA 125 were 35-96%, sensitivity and specificity of CA 19-9 were 47-100% in gastric cancer, respectively. In conclusion, tumor markers, especially CA 125 and CA 19-9 can be used in clinical applications (e.g. diagnosis, preoperative evaluation and follow up etc.) of gastric cancers.

Özet

Bu çalismada; 112 olguda (75 erkek, 37 kadin) tümör "marker"larindan AFP, CEA, CA 125, ve CA 19-9'un mide kanserlerinin tanisi, klinik kullanimlarindaki yeri ve sensivitivite-spesifisite degerlerinin karislastirilmasi amaçlandi. Mide kanserli hasta grubu: 57 hastanin (38 erkek, 19 kadin) yas ortalamasi 55.36±1.37 yil, benign hasta grubu: 30 hastanin (20 erkek, 10 kadin) yas ortalamasi 53.53±1.97 yil, kontrol grubu: 25 saglikli bireyin (17 erkek, 8 kadin) yas ortalamasi 57.11±2.87 yil idi. Istatistiksel olarak gruplar arasinda yas ve cinsiyet farki bulunmadi (p>0.05). Mide kanserli hastalarin preoperatif tümör "marker" degerlerine göre; CEA, CA 125 ve CA 19-9 seviyeleri benign hastalikli ve kontrol grubuna göre anlamli derecede yüksekti (p 0.05). Postoperatif degerler arasinda ise CA 19-9 benign hastalikli grubda anlamli bulundu (p<0,01). Mide kanserli olgularda AFP'in spesifitesi %100, sensitivitesi %3.5 iken CEA'in spesifitesi %100, sensitivitesi %63; CA 125'in spesifitesi %96, sensitivitesi %63; CA 19-9'un spesifitesi %100, sensitivitesi %47 olarak bulundu. Mide kanserlerinin teshisinde; CEA, CA 125, CA 19-9'un duyarli oldugu, postoperatif takip gibi klinik degerlendirmede özellikle CA 125 ve CA 19-9 'un prognostik degerlerinin daha fazla oldugu sonucuna varildi.

🔖

Cite This Article

ALTINBAŞ, E., POLAT, H., BORAZAN, A., YEKSAN, M., ECİRLİ, Ş. (2001). The clinical usefulness of the tumor markers; AFP, CEA, CA 125 and CA 19-9 in patients with gastric cancer. Selçuk Tıp Dergisi, Cilt: 17 - Sayı: 1, 37–42. https://ajindex.com/articles/319411

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Wyngaarden JB, Smith LH, Benneth JC. Cecil text- book of medicine 19th ed. Philadelphia: WB Saunders 1992; 667-1074
  2. Kadaydci A, Benekli M, Savas C. Turn& belirleyicileri. TOrkiye Tip Dergisi 1994; 1: 273-84
  3. Schwartz MK. Cancer markers. In: De Vita VT, Sa- muel H, Steven AR editors. Cancer principles and practice of oncology 4th ed. Philadelphia JB Lippincott 1993; 818-1006
  4. Van Dongen JA. Tumor markers-a tool for clinicians. Path Biol 1993; 41(1):27 5. Haskell MC. Cancer treatment third edition. WB Sa- unders 1990; chapter72:808
  5. Sakamoto K, Haga Y, Yoshimura R, Egami H, Yo- koyamaY, Akagi M. Comparative effectiveness of the tumor diagnostics. CA 19-9, CA 125, and CEA in pa- tients with disease of the digestive system. Gut 1987; 28 (3): 323-9
  6. Sell S. Cancer associated carbonhytrates identified by monoclonal antibodies. Human Pathol 1990; 21: 1003-19
  7. Longo DL. Tumor markers: Current status of the quest-introductory overview. Semin Oncol 1987; 14 (2): 85-8
  8. Haglund C, Roberts PJ, Jalanko H, Kuusela P. Tumor markers CA 19-9 and CA 50 in digestive tract -ma- lignancies. Scand J Gastroenterol 1992; 27 (3): 169- 74
  9. Kornek G, Depisch D, Temsch EM, Scheithauer W. Comparative analysis of cancer associated antigen CA 195, CA 19-9 and carcinoembriyonic antigen in di- agnosis, follow up and monitoring of response to che- motherapy in patients with gastrointestinal cancer. J Cancer Res Clin Oncol 1991; 117(5): 493-6
  10. Borlinghaus P, Lamerz R. Circulating tumor markers in gastrointestinal tumors. Le ber Magen Darm 1991; 21 (5): 199-202
  11. Hergeng G, Sahin H. kanser tam ye prognozunda tumor belirtegierinin Onemi. Sendrom 1994; 4: 50-5
  12. Ooi A, Nakanishi 1, Sakamoto N, Tsukada Y, Ta- kahashi Y, Minamato T, et al. AFP-producing gastric carcinoma. Cancer 1990; 65(8): 1741-47
  13. Yoshikawa T, Nishida K, Tanigawa M, Fukumoto K, Kondo M. CA 19-9 and other tumor markers in gast- rointestinal malignancies. Digestion 1985; 31(2-3): 67- 76
  14. Quentmeier A, Sontag P, Geisen HP, Schmidt-Gayk H. Evaluation of CA 125 as a tumor for gastric and co- lorectal cancer in comparison to CEA and CA 19-9. Eur J Surg Oncol 1987; 13(3): 197-201
  15. Wobbes T, Thomas MG, Segers MF, Nagengast FM. Evaluation of seven tumor markers ( CA 50, CA 19-9, CA 19-9 Truquant, CA 72-4, CA 195, CEA and tissue polipeptid antigen) in the pretreatment sera of patients with gastric carsinoma. Cancer 1992; 69(8): 2036-41 17. Kornek GV, Depisch D. Comparative analysis of C